Market Eyes LiveMerck & Co., Inc. (MRK) Stock Rating & Analysis
MELANY's data-driven read on Merck & Co., Inc. · Pharmaceutical Preparations.
Merck makes pharmaceutical products across several therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, its immuno-oncology platform led by Keytruda is a major sales contributor; it also has a substantial vaccine business targeting pediatric diseases plus Gardasil for human papillomavirus, and it sells animal health drugs. Geographically, 47% of sales come from US human health (pharmaceuticals and vaccines).
Why MRK scores 61/100
MELANY scores Merck & Co., Inc. 61/100 by weighing eight factors. Here is how MRK breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 23.8x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 75%
Direction and relative strength of the recent share-price trend.
- Price +17.0% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +21%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for MRK
- Trailing P/E 119x, priced for sustained growth, any miss could de-rate hard
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Merck & Co., Inc. sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds MRK's momentum and catalyst factors above.
MRK trade plan (members only)
MELANY has a full position plan for Merck & Co., Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates MRK
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Merck & Co., Inc.'s 61/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about MRK
Is Merck & Co., Inc. (MRK) a buy?
As of 2026-08-21, MELANY rated Merck & Co., Inc. Promising with a composite score of 61/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Merck & Co., Inc.'s MELANY score?
Merck & Co., Inc. (MRK) has a MELANY composite score of 61/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the MRK stock rating calculated?
MELANY scores MRK from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Merck & Co., Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Merck & Co., Inc. (MRK) Promising with a composite of 61/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the MRK stock price forecast?
MELANY does not publish price targets or forecasts for MRK. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 61/100 across eight factors for Merck & Co., Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is MRK stock overvalued or undervalued?
MELANY's valuation factor currently reads 39/100 for Merck & Co., Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MRK's read.
What price should I buy MRK at?
Rather than chasing the current price, MELANY computes a smart entry zone for MRK: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying MRK stock?
The top risks MELANY currently flags for Merck & Co., Inc.: Trailing P/E 119x, priced for sustained growth, any miss could de-rate hard; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Merck & Co., Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 47/100 for Merck & Co., Inc., and earnings track record, at 100/100. The 61/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will MRK stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 84/100 for MRK right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this MRK rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores MRK continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
MRK's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.